Arcturus Therapeutics Holdings Inc.
corporate_fare Company Profile
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for ARCT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for ARCT spans 8-K, 10-Q, 10-K.
Recent high-impact activity:
- Meiji Buys $50M of Arcturus Stock at 80% Premium, Expands mRNA Collaboration
- Arcturus Q3 10-Q: Loss Narrows to $7.4M, $184.8M Cash, CSL Exit Booked
- Q3 Net Loss Halves to $7.4M as Arcturus Guides Cash Runway to 2028
- FDA Endorses Ammonia as Key Pediatric Endpoint; Arcturus Adds ARCT-2601 to Phase 2 Trial
- Arcturus Buys AI Drug Discovery Firm myNEO, Reports Positive OTCD Data
Financial Snapshot
Short Interest & Short Volume
7.37 days to coverFINRA reported short interest of 5,409,475 shares in ARCT as of the October 30, 2026 settlement, a 0.9% decrease from the prior period — about 7.4 days to cover at its recent average daily volume. On November 20, 2026, 55.3% of ARCT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.